RNAZ

TransCode Therapeutics, Inc. is a clinical-stage oncology company focused on treating metastatic disease. The Company is focused on treating cancer through the design and delivery of ribonucleic acid (RNA) therapeutics based on its TTX nanoparticle platform. The Company’s lead therapeutic candidate, TTX-MC138, is focused on treating metastatic tumors which overexpress microRNA-10b, a unique, well-documented biomarker of metastasis. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 (PD-L1), and two indication agnostic programs, TTX-RIGA, an RNA-based agonist of the retinoic acid- inducible gene I (RIG-I), targeting activation of innate immunity in the tumor microenvironment; and TTX- CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells. The Company’s pipeline also includes TTX-mRNA, a tumor-type specific mRNA-based platform for the development of cancer vaccines.